Business ❯Pharmaceutical Industry

Novo Nordisk

Drug Development Financial Performance Eli Lilly Market Impact Sales Drug Sales Market Performance Drug Pricing Drug Profits Stock Market Market Analysis Research and Development Market Competition Market Dynamics Product Management Growth Driver Global Market Expansion Manufacturing Constraints Market Practices Product Offerings Sales Performance CEO Meetings CEO Testimony Drug Prices Future Plans Sales Growth Key Drugs Stock Performance Company Strategy Economic Impact Weight Loss Drugs Semaglutide Wegovy CEO Statements Drug Production

FDA Ends GLP-1 Drug Shortages, Triggering New Pricing and Coverage Moves

Novo Nordisk and Cigna introduce temporary discounts and copay caps as compounded semaglutide distribution ceases under new FDA regulations.

Minnesota Secures $35 Monthly Insulin Cap in Landmark Settlement with Novo Nordisk

Trump's Tariff Threat Over Greenland Could Drive Up Prices for Key Danish Exports

Government Plans Dominate Coverage for Costly Weight-Loss Drugs

Novo Nordisk's Weight-Loss Drugs Boost Danish Economy Amid Local Health Challenges

Novo Nordisk Urges FDA to Ban Compounded Versions of Ozempic and Wegovy

Bernie Sanders and Elon Musk Unite on Lowering Ozempic Prices

Senate Grills Novo Nordisk CEO Over High U.S. Prices for Ozempic and Wegovy

Bernie Sanders Pushes for Cheaper Ozempic Amid Medicare Price Negotiations

Lawsuit Highlights Severe Side Effects of Popular Weight-Loss Drugs

Weight Loss Drugs Significantly Reduce COVID-19 Mortality

Novo Nordisk CEO to Testify on High US Drug Prices

Novo Nordisk's Weight Loss Drug Wegovy Launches in UK Amid High Demand and Limited Supply

New Weight Loss Pill Could Compete with Popular Injection